ArteraAI vs Nucs AI (2026)
Two companies working prostate cancer from different raw materials. ArteraAI builds multimodal tests combining image derived signal from tissue with clinical data, validated against treatment decisions, and reaching beyond one tumour type. Nucs works the imaging pathway, with products spanning automated analysis and the theranostics workflow around specialised prostate imaging. A prostate service could use both at different points, since one informs whether to treat more aggressively and the other supports how the disease is imaged and targeted. Neither carries a reviewed performance claim for its prognostic output, so the validation cohort is the thing to interrogate, particularly how well it matches your own population by stage, ancestry and treatment era.
- It builds multimodal cancer tests validated against treatment decisions, which is a different evidentiary object from a single slide model.
- The prognostic question sits inside a genuinely uncertain treatment decision, which is where a test can change management rather than confirm it.
- Breadth beyond one tumour type gives an oncology service more than one place to use it.
- It covers the prostate cancer pathway around specialised imaging, with products spanning automated analysis and the theranostics workflow.
- Depth in one disease across several products means the outputs connect rather than each standing alone.
- For a prostate service running specialised imaging, a pathway product fits how that service actually works.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. ArteraAI and Nucs AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards ArteraAI its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Nucs AI, ArteraAI grades higher on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Nucs AI its top capability grade on AI Centrality. Set against ArteraAI, Nucs AI does not grade higher on any scored axis, though the two are level on AI Centrality and EHR and Interoperability Depth. Its thinnest published disclosure sits on AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose ArteraAI or Nucs AI?
The AI Health Index grades ArteraAI higher than Nucs AI on every axis that separates them, several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Nucs AI does not grade higher on any scored axis.
Where do ArteraAI and Nucs AI differ most?
The widest separation the AI Health Index records between ArteraAI and Nucs AI is on Model and Technology Transparency, where ArteraAI grades A and Nucs AI grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do ArteraAI and Nucs AI grade the same?
The AI Health Index grades ArteraAI and Nucs AI the same on AI Centrality and EHR and Interoperability Depth. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have ArteraAI and Nucs AI not disclosed?
At the last review, at least one of ArteraAI and Nucs AI published thin or absent detail on AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These serve the same cancer from different modalities, one from tissue and one from imaging, and a prostate service may use both at different decision points. Neither is a cleared device in the sense of a reviewed performance claim for the prognostic output, so the validation cohorts are what a buyer should interrogate, including how closely they match the local population by stage, ancestry and treatment era. Neither publishes pricing, a security attestation or a subgroup performance analysis.